Results 61 to 70 of about 35,072 (188)

Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases

Pediatric Rheumatology Online Journal
Background In pediatric rheumatic diseases (PRD), adalimumab is dosed using fixed weight-based bands irrespective of methotrexate co-treatment, disease activity (DA) or other factors that might influence adalimumab pharmacokinetics (PK).
Tatjana Welzel, Klervi Golhen, Andrew Atkinson, Verena Gotta, David Ternant, Jasmin B. Kuemmerle-Deschner, Christine Michler, Gilbert Koch, Johannes N. van den Anker, Marc Pfister, Andreas Woerner   +10 more
doaj   +1 more source

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

Arthritis Research & Therapy, 2021
Background To demonstrate equivalent efficacy of the proposed high-concentration (100 mg/ml), citrate-free adalimumab biosimilar CT-P17 to European Union-approved adalimumab (EU-adalimumab) in subjects with active rheumatoid arthritis (RA).
Jonathan Kay, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec, Slawomir Jeka, Agnieszka Zielinska, Jakub Trefler, Katarzyna Bartnicka-Maslowska, Magdalena Krajewska-Wlodarczyk, Piotr A. Klimiuk, Sang Joon Lee, Yun Ju Bae, Go Eun Yang, Jae Kyoung Yoo, Daniel E. Furst, Edward Keystone   +17 more
doaj   +1 more source

Levels of antibodies to adalimumab in children with juvenile idiopathic arthritis at different stages of treatment

Zdorovʹe Rebenka, 2023
Background. Juvenile idiopathic arthritis (JIA) is one of the most common rheumatological diseases of childhood. The central place in the problem of JIA belongs to the question of treatment the timeliness and adequacy of which determine the disease ...
T.V. Marushko, O.Ye. Onufreiv, Yu.V. Marushko, O.B. German   +3 more
doaj   +1 more source

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

Scientific Reports, 2021
To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induced by the ADA ...
L. Cingolani, B. Barberio, F. Zingone, A. Ferronato, L. Bertani, F. Costa, G. Bodini, M. Demarzo, P. Melatti, A. Gubbiotti, D. Massimi, Cesare Casadei, R. D'Incà, E. Savarino   +13 more
semanticscholar   +1 more source

Blue Ear Drum as an Unusual Adverse Effect of Adalimumab: A Case Report

Central Asian Journal of Medical Hypotheses and Ethics
Adalimumab has been employed for an extended period as an efficacious and secure agent for inflammatory bowel and rheumatic diseases. ABP 501 is one of the biosimilars of adalimumab and has a similar safety profile to that of the original adalimumab ...
Abdulvahap Kahveci, Murat Yaşar
doaj   +1 more source

Adalimumab induced psoriasis in a Crohn’s disease patient: a case report

Journal of the Pakistan Medical Association
Adalimumab is a human monoclonal antibody that selectively targets tumour necrosis factor-alpha (TNF- Alpha), a cytokine involved in the pathogenesis of various inflammatory and autoimmune disorders.
Dhaifallah Alrakawi Alenizi
doaj   +1 more source

Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA

Rheumatology and Therapy
This Summary of Research overviews the results of a study that looked at patient-reported outcomes in the VOLTAIRE-RA trial (NCT02137226), originally published in Rheumatology and Therapy.
Vibeke Strand
doaj   +1 more source

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

Annals of the Rheumatic Diseases, 2019
Background In SELECT-COMPARE, a randomised double-blind study, upadacitinib 15 mg once daily was superior to placebo or adalimumab on background methotrexate (MTX) for treating rheumatoid arthritis signs and symptoms and inhibited radiographical ...
R. Fleischmann, M. Genovese, J. Enejosa, E. Mysler, L. Bessette, C. Peterfy, P. Durez, A. Ostor, Yihan Li, I. Song   +9 more
semanticscholar   +1 more source

Shift From Adalimumab Originator to Biosimilars in Denmark.

JAMA Internal Medicine, 2020
This study describes the nationwide shift from brand-name adalimumab (originator) to adalimumab biosimilars in Denmark and analyzes what a similar shift in the US would look like.
T. Jensen, Seoyoung C. Kim, E. Jimenez‐Solem, Dorthe Bartels, H. R. Christensen, J. Andersen   +5 more
semanticscholar   +1 more source

Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.

JAMA dermatology, 2022
Z. Yiu, G. Becher, B. Kirby, P. Laws, N. Reynolds, Catherine H. Smith, R. Warren, C. Griffiths   +7 more
semanticscholar   +1 more source